

Novel and Recurrent *BRCA1/BRCA2* Germline Mutations in Patients with Breast /Ovarian Cancer: A Series from the South of Tunisia

Dorra Ben Ayed-Guerfali

Center of Biotechnology of Sfax

Wala Ben Kridis-Rejab

Habib Bourguiba Hospital, Sfax, Tunisia

Nihel Ammous-Boukhris

Center of Biotechnology of Sfax

Wajdi Ayadi

Center of Biotechnology of Sfax

Slim Charfi

Habib Bourguiba Hospital, Sfax, Tunisia

Afef Khanfir

Habib Bourguiba Hospital, Sfax, Tunisia

Tahia Sellami-Boudawara

Habib Bourguiba Hospital, Sfax, Tunisia

Mounir Frikha

Habib Bourguiba Hospital, Sfax, Tunisia

Jamel Daoud

Habib Bourguiba Hospital, Sfax, Tunisia

Raja Mokdad-Gargouri (✉ raja.gargouri@cbs.mrt.tn)

Center of Biotechnology of Sfax <https://orcid.org/0000-0003-1319-0061>

Research

Keywords: Breast/ovarian cancer, BRCA1, BRCA2, germline mutation, genetic testing

Posted Date: November 19th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-108557/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Translational Medicine on March 16th, 2021. See the published version at <https://doi.org/10.1186/s12967-021-02772-y>.

Abstract

Background: The incidence of breast/ovarian cancer is increasing in Tunisia especially in young women and mostly those with family history. However, the spectrum of BRCA mutations remains little explored in Tunisian patients in particular in the southern region.

Methods: We sequenced the entire coding regions of *BRCA1* and *BRCA2* genes using Next Generation Sequencing (NGS) in 134 selected patients with breast/ovarian cancer.

Results: Among the 134 patients, 19 (14.17%) carried pathogenic mutations (10 are *BRCA1* mutation carriers and 9 are *BRCA2* mutation carriers) that are mainly frameshift indel (76.9%). Interestingly, 5 out of the 13 variants (38.46%) were found at least twice in unrelated patients, as the c.1310_1313 delAAGA in *BRCA2* and the c.5030_5033 delCTAA that has been identified in 4/98 BC patients and in 3/15 OC patients from unrelated families with strong history of cancer. Besides recurrent mutations, 6 variant (4 in *BRCA1* and 2 in *BRCA2*) were not reported previously. Furthermore, 3 unrelated patients carried the VUS c.9976A>T, (K3326*) in *BRCA2* exon 27. *BRCA* carriers correlated significantly with tumor site ($p=0.029$) and TNBC cases ($p=0.008$). In the groups of patients (31-40 y and 41-50 y), *BRCA1* mutations occurred more frequently in patients with OC than those with BC, and conversely *BRCA2* carriers are mostly affected with BC ($p=0.001$ and $p=0.044$ respectively).

Conclusions: The overall frequency of the BRCA germline mutations was 14.17% in patients with high risk of breast/ovarian cancer. We identified recurrent mutations as the c.1310_1313 delAAGA in *BRCA2* gene and the c.5030_5033 delCTAA in *BRCA1* gene that were found in 4% and 20% of familial BC and OC respectively. Our data will contribute in the implementation of genetic counseling and testing for families with high-risk of breast/ovarian cancer.

Background

Breast cancer is the most prevalent cancer worldwide and the second leading cause of death by cancer in women [1, 2]. In Tunisia, the incidence of BC is 27.1/100.000/per year affecting more often young women (< 35 years), and with more aggressive clinical behavior [3, 4]. Approximately 5 to 10% of breast cancer patients harbor germline mutations that predispose to this malignancy at earlier onset compared to the general population [5, 6].

Evidently, the breast cancer susceptibility genes *BRCA1* (MIM# 113705) and *BRCA2* (MIM# 600185) are tumor suppressor genes that play a key role in DNA repair in the homologous recombination pathway [7, 8]. Therefore, loss of BRCA function can lead to an inefficient DNA repair process that increases mutation rates and thus contributes to the tumor development [9, 10]. Indeed, women carrying pathogenic germline mutations in *BRCA1/BRCA2* genes have an increased risk of breast/ovarian cancer compared to those with wild type *BRCA* genes [11–13]. Screening of *BRCA1/BRCA2* genes for the identification of pathogenic mutations is essential to provide genetic counseling to the members of affected families, for medical follow-up, and for the targeted therapy selection which is based on the inhibitor of poly-ADP-ribose polymerase inhibitor namely the Olaparib [14]. Despite the importance of the mutational spectrum of *BRCA1/BRCA2* genes, only few studies using Sanger DNA sequencing, investigated Tunisian patients with familial breast/ovarian cancers. In a recent study, Laitamn et al. reported all the pathogenic variants in both *BRCA1* and *BRCA2* genes in the Middle East, North Africa, and Southern Europe [15]. The authors identified 232 and 239 pathogenic sequence variants in *BRCA1* and *BRCA2*, respectively that include only few variants that were found in Tunisian patients [15].

Besides, Riahi et al. reported twelve pathogenic mutations (25%); among them, three were found in *BRCA1* (c.211dupA c.5266dupC and c.1504_1508delTTAAA) and two were novel mutations detected in *BRCA2* (c.1313dupT in and c.7654dupT). The study was carried out on 92 families and was performed by direct sequencing [16]. Furthermore, two other studies reported deleterious mutations of the *BRCA1/BRCA2* genes in 19% and 18% of familial patients from the north region of Tunisia respectively [17, 18]. Moreover, Fourati et al. by targeting the exons 5,11, and 20 of the *BRCA1* gene and exons 10 and 11 of the *BRCA2* gene, showed that among 66 patients, 12 patients (18%) had deleterious mutations in the *BRCA1* or *BRCA2* genes [19].

The study of Mahfoudh et al. included 16 Tunisian high-risk breast cancer families and they were screened for only *BRCA1* gene. The authors showed that the prevalence of *BRCA1* carriers was 37.5% and identified 3 truncating mutations (916 delTT, 3450 delCAAG, 5382 insC) and one splice site mutation c.212 +2insG [20].

Technological advances in DNA sequencing have improved and facilitated the screening procedure of *BRCA1/BRCA2* genes since the large sizes of these genes and the absence of hotspots regions make this procedure expensive and time-consuming. In fact, NGS has resolved these problems and allows, henceforth the detection of mutations with higher sensibility [21–23]. Our study is the first using NGS to screen the whole exons of *BRCA1/BRCA2* genes in 134 selected patients with high risk of breast or/and ovarian cancer in the south region of Tunisia.

Methods

Patients

A total of 134 patients were selected (between 2016-2019) among them 113 patients with familial history of breast (98 cases) and/or ovarian cancer (15 cases) that meet the following criteria: 1) at least 1 first- and/or second-degree relative with breast and/or ovarian cancer; 2) younger than 35 years of age at breast cancer, 3) male breast cancer, 4) ovarian cancer at early age.

In addition, 21 cases without evidence of family history were included in this study, 12 were diagnosed with BC at the age ≤40, and 9 patients diagnosed with OC at the age ≤60 years. All patients were recruited from the department of Medical Oncology of the CHU Habib Bourguiba of Sfax (Tunisia), and had provided written informed consent for participation in the research study and for the genetic testing.

Genetic testing

Genomic DNA was isolated from 0.2 mL of peripheral blood of the proband from each selected family using the "QIAamp DNA Blood Mini kit" (Qiagen), following the manufacturer's instructions. Isolated DNA was quantified by Qubit 3.0 Fluorometric quantitation (Thermo Fisher Scientific). The *BRCA/BRCA2* germline mutations were detected using the next-generation sequencing approach (NGS). Briefly, 50 ng of genomic DNA from each sample was used to prepare library using the "AmpliSeq™BRCA Panel", "AmpliSeq™Library Plus" and "AmpliSeq™CD Indexes" according to the protocol provided by Illumina. The adaptors and sample unique DNA barcodes were incorporated into the amplified amplicons with a second PCR. Libraries were quantified with the Qubit® dsDNA HS Assay Kit (Life Technologies). The DNA library was pooled and prepared for sequencing using the Illumina MiSeq sequencer with Miseq Reagent Kit v2 (300-cycles) (Illumina, San Diego, CA) according to the manufacturer's instructions to generate paired-end reads with a 151-bp read length. Reads were trimmed to remove low-quality sequences and then aligned to the human reference genome (GRCh37/hg19) using the Burrows-Wheeler alignment (BWA) package.

The *BRCA1* (NM_007300.3) and *BRCA2* (NM_000059.3) sequences from the National Center for Biotechnology Information (NCBI) database (<http://www.ncbi.nlm.nih.gov>) were used as reference. The NGS data was analyzed using the BaseSpace Variant Interpreter (<https://basespace.illumina.com>).

Sanger sequencing was performed to confirm the *BRCA1/BRCA2* pathogenic mutation identified by NGS. Sequencing primers were designed using Primer 5.0 software and provided on request. PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) and labeled using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), and the sequence analysis was performed by BioEdit.

Variant annotation and classification

We annotated the mutations using in silico prediction tools to evaluate the functional effects of the candidate variants: PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>), Sorting Intolerant From Tolerant (SIFT) (<http://sift.jcvi.org/>), and Mutation Taster (<http://www.Mutationtaster.org/>).

Statistical analysis

Associations between patient characteristics and presence of pathogenic *BRCA1/BRCA2* mutations were tested by χ^2 test. A significance level of $p \leq 0.05$ was used in the analysis. All analyses were performed using SPSS (version 20.0)

Results

Patients characteristics

A total of 134 breast and/or ovarian cancer subjects were included in this study. The characteristics of the study group are presented in Table 1. Unilateral BC was diagnosed in 104 (77.6%) patients, 6 (4.5%) women had bilateral BC, 22 (16.4%) had OC, and 2 (1.5%) had both BC and OC. Age at diagnosis of breast cancer ranged from 27 to 65 years (median: 42.78 years), and of ovarian cancer ranged from 38 to 64 years (median: 50.37 years). For patients with breast cancer only 9 (6.7%) were diagnosed before the age of 30 years and 55/134 (41%) before 40 years of age. In the group of patients with ovarian cancer, only 4 patients were diagnosed at an age ≤ 40 years. Family history of BC and/or OC was found in 113 (84.3%) patients. Among the 21 patients without family history of BC/OC, 12 were diagnosed with TNBC and 9 with OC (Table 1).

BRCA1/ BRCA2 germline pathogenic mutations

Pathogenic *BRCA1/BRCA2* germline mutations were identified in 14.17 % (19/134) of the patients (Fig.1, Table 2). Among 113 patients with strong family history for breast/ovarian cancer (HBOC), 18 (15.9%) were positive for *BRCA* mutations (9 in *BRCA1* and 9 in *BRCA2*). In the group of patients without evidence of HBOC, including 12 patients with TNBC and 9 patients with OC, only one patient 4.8% (1/21) with OC carried the c.2338C>T (Gln780X) pathogenic *BRCA1* mutation and 2 cases (1 TNBC and 1 OC) carried the VUS c.9976A>T (Lys3326X) in *BRCA2* exon 27 (Fig.1, Tables 2,4). Most of the *BRCA* mutations were pathogenic (class 2 to 6) and 76.9% of the mutation (10/13) were frameshift deletion, only 1 was frameshift duplication, 2 nonsens mutations and one splice site mutation (Table 2, Fig.1). Among the 13 mutations detected, 5 were identified at least twice in unrelated patients. Notably, the frameshift mutation c.1310_1313delAAGA of the *BRCA2* gene was detected in 4 unrelated BC patients, and the c.17-20 delAAGA in 2 unrelated young patients with strong family history of BC. In *BRCA1*, the c.5030_5033delCTAA was found in 3 unrelated young patients (≤ 40 years) diagnosed with OC (2 without and 1

with BC), and the c.2338C>T mutation was detected in 2 unrelated patients with OC only. Interestingly, our data indicated that the c.1310_1313delAAGA of the *BRCA2* gene, and the c.5030_5033delCTAA of the *BRCA1* gene were found in 4% (4/98) and in 20% (3/15) of familial BC and of early onset familial OC respectively. We also detected the c.632-1G>A mutation in the splice acceptor site in 2 patients with BC (Table 2, Fig.2). It is interesting to note that the 2 unrelated patients with the c.632-1G>A variant, carried also the pathogenic mutation c.1310_1313delAAGA in *BRCA2*. Our study outlined 6 out of 13 (46%) novel pathogenic *BRCA* mutations, according to the BIC and ClinVar databases.

Association of BRCA carriers and clinico-pathological parameters

In breast cancer, there is a significant association between Triple Negative status and *BRCA* mutations. Among the 26 TNBC cases, 5 (19.23%) carried *BRCA* mutations and 4 (80%) were *BRCA1* mutation carriers ($p=0.008$, Table 1). Additionally, patients with ovarian cancer (with or without breast cancer) carried only mutations in *BRCA1* gene as opposed to *BRCA2* gene (5/24 vs 0/24), whereas *BRCA2* mutations were more frequently detected in patients with only breast cancer (9/110 vs 5/110, $p=0.029$, Table 1). No other associations were observed with clinico-pathological parameters (Table 1).

On the other hand, for patients diagnosed with breast cancer at an age ≤ 30 years, the *BRCA* mutation rate was 22.2% (2/9), and none of the patients was diagnosed with ovarian cancer at an age ≤ 30 years in our series. In the group of patients between 31 and 40 years, *BRCA* mutation was detected in 13.72% (7/51) and in 75% (3/4) of women diagnosed with BC and OC respectively ($p=0.001$, Fig.2a,b; Table 3). Concerning women aged from 41 to ≤ 50 years old diagnosed with BC or OC, 8.33% (2/24) and 22.2% (2/9) carried a *BRCA* mutation respectively ($p=0.044$, Fig.2a,b; Table 3). None of OC patients over 51 years carried *BRCA* mutation while 11.5% (3/26) of BC patients were *BRCA2* carriers (Fig.2a, b; Table 3). The mutation rate for the *BRCA* gene in patients with only ovarian cancer was 18.2% (4/22), all were *BRCA1* carriers and only one OC patient carried the variant K3326X in the *BRCA2* gene (Tables 1, 3). Furthermore, in young patients (≤ 30 years), 40% (2/5) of TNBC carried *BRCA* mutation while in the group of TNBC patients aged from 31 to 40 years old, *BRCA* mutations occurred more frequently in *BRCA1* than in *BRCA2* gene (3/13, (23%) vs 0/13 (0%), ($p=0.041$, Fig.2c, Table 3)).

Variants of uncertain significance in *BRCA1/BRCA2* genes

In addition to deleterious *BRCA1/BRCA2* mutations, 10 VUS (6 in *BRCA1* and 4 in *BRCA2*) were predicted to be pathogenic by PolyPhen, SIFT or Mutation Taster (Table 4). Each VUS was identified in more than one patient and the c.9976A>T in exon 27 of the *BRCA2* gene was detected in 3 unrelated patients, 2 with BC diagnosed at an age ≤ 40 years and 1 patient with OC (Table 4). All VUS have been reported in the BIC database except the variant N550H in *BRCA1* exon 11.

Discussion

BRCA1 and *BRCA2* have key roles in the development of breast/ovarian cancer [9, 10]. The prevalence of *BRCA1/BRCA2* mutations varies in different populations due to founder mutation effect [15, 24–28]. Genetic testing of patients with family history for breast/ovarian cancer have become standard clinical management in Western countries, however, in Tunisia studies of *BRCA*-associated breast/ovarian cancer remain less investigated. Clearly, the majority of studies that reported the spectrum of *BRCA* mutations in Tunisia included a small number of patients and used Sanger method for DNA sequencing [16–20]. Riahi et al. reported that the rate of *BRCA* mutations in patients from the north of Tunisia was 25% (12/48) [16]. Furthermore, in another study, it was showed that

deleterious *BRCA1* mutations were detected in 37% (6/16) of patients selected from high-risk breast cancer families [20]. In this study, we used NGS to determine the *BRCA* mutation rates in high risk breast and/or ovarian cancer in patients from the south of Tunisia. Thirteen truncating mutations and one splice acceptor mutation were identified in 19 among 134 patients (14.17%). The rate of *BRCA1* mutations found in this study (7.46%, 10/134) was lower than those reported in previous studies. In fact, in a review of the literature, Cherbal et al., reported that in breast/ovarian cancer families from Algeria, Morocco and Tunisia, *BRCA1* was mutated in 17.43% of cases (34/195) and that the c.798_799delTT was a recurrent mutation [29]. In our study none of the previously reported mutations in North African patients was identified except for the c.1310_1313delAAGA in *BRCA2*. Indeed, this mutation was detected in 4% (4/98) of patients from unrelated families with high risk of breast cancer and among 9 *BRCA2* carriers, 4 (44.4%) had the c.1310_1313delAAGA mutation suggesting that it might be recurrent in our population. Our finding is in line with a previous study showing that the c.1310_1313delAAGA mutation was detected in 6% (4/66) of patients from the north of Tunisia [19]. Furthermore, it was reported that the c.1310_1313delAAGA mutation was detected in 11.4% (14/122) of patients from the North-East region of Morocco, and in one Algerian family among 10 carrying *BRCA* mutation [30, 31]. According to the Breast Cancer Information Core database (BIC; <http://research.nhgri.nih.gov/bic/>), this mutation was found in different European patients and was recorded several times in the French UMD-BRCA2 database and classified as founder mutation [32]. Furthermore, we found that 2 BC patients are double heterozygous carrying both the c.1310_1313delAAGA frameshift mutation and the splice site acceptor variant c.-632G < A. This splicing mutation has been reported two times in the ClinVar database therefore, and in the best of our knowledge this is the first report describing the association of the splice site and a frameshift mutation in the *BRCA2* gene in 2 unrelated patients with strong family history of breast cancer.

The pathogenic mutation c.17–20 delAAGA (Lys6Xfs) in *BRCA2* exon 2 was detected in 2 unrelated young patients (39 year-old) with strong family history of breast cancer. This mutation has not been reported previously in the ClinVar and BIC databases.

We also detected the c.9976A > T (K3326X) in 3 unrelated patients, 2 were diagnosed with family breast cancer at 28 and 36 years old and one patient with ovarian cancer at 56 years old and without family history. The *BRCA2* variant (K3326X), was firstly interpreted as pathogenic, but its identification in control populations led to its classification as a benign polymorphism [33]. However, recent studies showed the association of K3326X variant with the risk of developing melanoma, pancreatic, breast and ovarian cancers [34–36]. Moreover, the large study of Meeks et al., provided evidence that the K3326X variant is associated with the risk of developing breast and ovarian cancers independently of other pathogenic variants in *BRCA2* [37]. Altogether, it was suggested that the K3326X variant is not neutral and that it may be included in SNP panels for evaluating breast cancer risk.

In *BRCA1* gene, we identified the c.5030_5033delCTAA mutation in 3 out of 15 (20%) unrelated patients with early onset familial. This mutation has not been reported in North Africa but was found in patients from Greece, Italy, Jordan, Lebanon, Kuwait, and Saudi Arabia [15]. In addition, the nonsense mutation c.2338C > T was shared by 2 young patients (< 50 years-old) diagnosed with ovarian cancer. The c. 2338C > T has been reported in Caucasian patients according to the BIC and ClinVar databases. Altogether, these findings may suggest ethnic and genetic associations between unrelated populations, or that these mutations occur in mutational hotspots region.

On the other hand, it is interesting to note that the *BRCA* mutation rate in young patients diagnosed with breast cancer (age \leq 30 years) was higher (22.2%) compared to older patients (13.7% (31–40), 8.3% (41–50), and 11.5% (\geq 51 years)). The recent study of Bakkach et al. reported that the frequency of mutations among young patients (\leq

40 years) with family history of breast cancer was 16.7% (5 out of 33 patients) suggesting that the young age for breast cancer diagnosis seems to be strongly predictive of BRCA mutation status in Moroccan patients [38].

Of patients with ovarian cancer (with and without breast cancer), 20.83% (5/24) carried pathogenic variants. Mutation detection rates were 75% (3/4) for patients diagnosed between 31 and 40 years compared to only 22.2% (2/9) for women between 41 and 50 years. All patients over 51 years, carried no mutations in *BRCA1/BRCA2* genes.

It is well established that TNBC exhibit an aggressive behavior and has a worse prognosis [39]. In our cohort, among 110 patients with only breast cancer, 26 (23.6%) were TN including 14 patients with family history of breast cancer and 12 without evidence of family history of breast/ovarian cancer. Five patients (5/26, 19.23%) carried *BRCA* mutations and 4 among them (80%) were *BRCA1* carriers. Consistent with our findings, in a previous study, the *BRCA1* mutation carriers had a higher incidence in TNBC than *BRCA2* mutation carriers [41–43]. Moreover, in a recent work, Toss et al. showed that in TNBC Italian patients, *BRCA* mutation prevalence was 22.6% (21.4% *BRCA1*) and that 64.2% are ≤ 30 years old, which is in line with our findings [44]. Furthermore, Mahfoudh et al. reported that the 5382insC mutation in *BRCA1* was detected in 25% (2/8) of Tunisian patients with TNBC [45]. In our study, none of the patients carried the *BRCA1* 5382insC mutation, however, in TNBC we detected 3 mutations in *BRCA1* (c.3254delG, c.3364_3370dupACAGATT, c.4067_4071delAAGAA), and no *BRCA2* pathogenic mutations were detected in TNBC cases except the VUS c.9976A > T identified in 2 unrelated patients.

Our study has some limitations: (i) the small number of patients enrolled, (ii) the analysis of large *BRCA* gene rearrangements in patients who were negative for *BRCA1/BRCA2* mutations, and (ii) the screening of minor predisposing genes as *PALB2*, *PTEN*, *TP53*, *RAD51C*.

Conclusions

This study assessed the prevalence of germline mutations and identified novel and recurrent mutations for *BRCA1/BRCA2* genes in patients with high risk of breast/ovarian cancer from the south region of Tunisia. Giving the high prevalence of pathogenic mutations in *BRCA1/BRCA2* genes (14.17%), our data will contribute to the establishment of a service dedicated to the genetic screening and to the counseling of the families with high risk of hereditary breast/ovarian cancer in Tunisia.

Abbreviations

BRCA1: BR Breast CAncer susceptibility gene 1; BRCA2: BR Breast Cancer susceptibility gene 2; BIC: Breast cancer Information Core; BC: Breast Cancer; OC: Ovarian Cancer; ER: Estrogen Receptor; PR: Progesteron Receptor; HER2: Human Epidermal growth factor Receptor 2; TNBC: Triple Negative Breast Cancer; NGS: Next Generation Sequencing; VUS: Variant of Uncertain Significance.

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of the CHU Habib Bourguiba of Sfax-Tunisia. All patients provided written informed consent prior to their participation.

Consent for publication

Not applicable.

Availability of data and materials

All data generated are included in this article. Raw data are not publically available due to protect the confidentiality of patients, but are available from the corresponding author on request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by a grant of the CIC (Centre d'Investigation Clinique) and The Ministry of Higher Education and Scientific Research of Tunisia

Authors' contributions

WBK did the selection of families and patient recruitment. DBAG, NAB, WA performed experiments (DNA extraction, NGS and Sanger sequencing) and data compilation. SC, TSB performed the IHC of ER, PR and Her-2. RMG was involved in writing the manuscript, data analysis and bioinformatics analysis. AK, MF, JD contributed in the interpretation of results, and funding acquisition. All authors read and approved the final manuscript.

Acknowledgements

The authors thank the patients involved in the study.

References

1. Coleman MP, Quaresma M, Berrino F, Lutz J, de Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol.* 2008;9:730–56.
2. GLOBOCAN Breast cancer incidence and mortality worldwide, 2012. International agency for research on cancer. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. (2012)
3. Missaoui N, Jaidene L, Abdelkrim SB, Abdelkader AB, Bezig N, Yaacoub LB, et al. Breast cancer in Tunisia: clinical and pathological findings. *Asian Pacific J Cancer Prev.* 2011;12:169-72.
4. Ben Abdallah M, Zehani S, Maalej M, Hsairi M, Hechiche M, Ben Romdhane K, et al. Cancer du sein en Tunisie: caractéristiques épidémiologiques et tendance évolutive de l'incidence. *Tunis Med.* 2009;87: 417-25.
5. Foulkes WD. Inherited susceptibility to common cancers. *N Engl J Med.* 2008; 359:2143–53.
6. Peto J, Collins N, Batfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. *J Natl Cancer Inst.* 1999; 91:943–9.
7. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. *J Cell Sci.* 2001;114: 3591-8.
8. Deng CX, Wang RH. Roles of BRCA1 in DNA damage repair: a link between development and cancer. *Hum Mol Genet.* 2003;12: 113-23.
9. Yoshida K, Miki Y. Role of *BRCA1* and *BRCA2* as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. *Cancer Sci.* 2004;95: 866-71.

10. Jasin M. Homologous repair of DNA damage and tumorigenesis: the *BRCA* connection. *Oncogene*. 2002; 21: 8981-93.
11. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet*. 2003;72:1117-30.
12. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for *BRCA1* mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst*. 2002;94:1365-72.
13. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for *BRCA1* and *BRCA2* mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst*. 2013;105:812-22.
14. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: A proof-of-concept trial. *Lancet*, 2010; 376: 235-44.
15. Laitman Y, Fribel TM, Yannoukakos D, Fostira F, Konstantopoulou I, Figlioli G, et al. The spectrum of *BRCA1* and *BRCA2* pathogenic sequence variants in Middle Eastern, North African, and South European countries. *Hum. Mutat*. 2019;40:e1–e23
16. Riahi A, Ghourabi ME, Fourati A, Chaabouni-Bouhamed H. Family history predictors of *BRCA1/BRCA2* mutationstatus among Tunisian breast/ovarian cancer families, *Breast. Cancer*. 2017;24: 238-44.
17. Riahi A, Kharrat M, Ghourabi ME, Khomsi F, Gamoudi A, Lariani I, et al. Mutation spectrum and prevalence of *BRCA1* and *BRCA2* genes in patients with familial and early-onset breast/ovarian cancer from Tunisia. *Clin Genet*. 2015;87:155–60.
18. Troudi W, Uhrhammer N, Sibille C, Dahan C, Mahfoudh W, Bouchlaka Souissi C, et al. Contribution of the *BRCA1* and *BRCA2* mutations to breast cancer in Tunisia. *J Hum Genet*. 2007;52:915-20.
19. Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, et al. Screening for common mutations in *BRCA1* and *BRCA2* genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. *Bull Cancer*. 2014;101: e36-40.
20. Mahfoudh W, Bouaouina N, Ben Ahmed S, Gabbouj S, Shan J, Mathew R, et al. Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder *BRCA1* mutations in the Tunisian population. *Mol Biol Rep*. 2012;39:1037-46.
21. Chan M, Ji SM, Yeo ZX, Gan L, Yap E, Yap YS, et al. Development of a next-generation sequencing method for *BRCA* mutation screening: A comparison between a high-throughput and a benchtop platform. *J Mol Diag*. 2012; 14: 602-12.
22. Park K, Kim MK, Lee T, Hong J, Kim HK, Ahn S, et al. Performance evaluation of an amplicon-based next-generation sequencing panel for *BRCA1* and *BRCA2* variant detection. *Clin Lab Anal*. 2020;19:e23524.
23. Sim WC, Lee CY, Richards R, Bettens K, Mottier V, Goh LL. Validation of a next generation sequencing assay for *BRCA1*, *BRCA2*, *CHEK2* and *PALB2* genetic testing. *Exp Mol Pathol*. 2020;116:104483. doi: 10.1016/j.yexmp.2020.104483.
24. Díez O, Osorio A, Durán M, Martínez-Ferrandis JI, de la Hoya M, Salazar R, et al. Analysis of *BRCA1* and *BRCA2* genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. *Hum Mutat*. 2003;22:301-12.

25. Lieberman S, Tomer A, Ben-Chetrit A, Olsha O, Strano S, Beeri R, et al. Population screening for *BRCA1/BRCA2* founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. *Genet Med.* 2017;19:754-62.
26. Alvarez C, Tapia T, Perez-Moreno E, Gajardo-Meneses P, Ruiz C, Rios M, et al. *BRCA1* and *BRCA2* founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. *Oncotarget.* 2017;8:74233-43.
27. Bu R, Siraj AK, Al-Obaisi KA, Beg S, Al Hazmi M, Ajaram D, et al. Identification of novel *BRCA* founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. *Int J Cancer.* 2016;139:1091-7.
28. Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, et al. *BRCA* genetic screening in Middle Eastern and North African: mutational spectrum and founder *BRCA1* mutation (c.798_799delTT) in North African. *Dis Markers.* 2015; 194293. doi: 10.1155/2015/194293.
29. Cherbal F, Bakour R, Adane S, Boualga K. *BRCA1* and *BRCA2* germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. *Breast Dis.* 2012;34:1-8.
30. Laarabi FZ, Ratbi I, Elalaoui SC, Mezzouar L, Doubaj Y, Bouguenouch L, et al. High frequency of the recurrent c.1310_1313delAAGA *BRCA2* mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control. *BMC Res Notes.* 2017;10:188.
31. Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P. *BRCA1* and *BRCA2* germline mutations screening in Algerian breast/ovarian cancer families. *Dis Markers.* 2010;28:377-84.
32. Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R, et al. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-*BRCA1/BRCA2* databases. *Nucleic Acids Res.* 2012;40:992-1002.
33. Thompson ER, Gorringe KL, Rowley SM, Li N, McInerny S, Wong-Brown MW, et al. Reevaluation of the *BRCA2* truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context. *Sci. Rep.* 2015;5:14800. doi: 10.1038/srep14800.
34. Tuominen R, Engstrom PG, Helgadottir H, Eriksson H, Unneberg P, Kjellqvist S, et al. The role of germline alterations in the DNA damage response genes *BRIP1* and *BRCA2* in melanoma susceptibility. *Genes Chromosom. Cancer.* 2016;55:601-11.
35. Martin ST, Matsubayashi H, Rogers CD, et al. Increased prevalence of the *BRCA2* polymorphic stop codon K3326X among individuals with familial pancreatic cancer. *Oncogene.* 2005;24(22):3652–3656.
36. Palmirotta R, Lovero D, Stucci LS, Silvestris E, Quaresmini D, Cardascia A, Silvestris F. Double Heterozygosity for *BRCA1* Pathogenic Variant and *BRCA2* Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family. *J Mol Sci.* 2018 Jan 18;19(1):285. doi: 10.3390/ijms19010285.
37. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, et al. *BRCA2* Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *J. Natl. Cancer Inst.* 2016;108 doi: 10.1093/jnci/djv315.
38. Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, El Fahime E, Barakat A, et al. Contribution of *BRCA1* and *BRCA2* germline mutations to early onset breast cancer: a series from north of Morocco. *BMC Cancer.* 2020; 20:859. doi: 10.1186/s12885-020-07352-9.
39. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol.* 2016; 13: 674-90.

40. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann. Surg. Oncol. 2013; 20:3254-8.
41. Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: Implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res. Treat. 2014; 145:707-4.
42. Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 2015;141:2005-12.
43. Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018;18:265. doi: 10.1186/s12885-018-4029-y
44. Toss A, Molinaro E, Venturelli M, Domati F, Marcheselli L, Piana S, et al. [BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy](#). Cancers (Basel). 2020;121252. doi: 10.3390/cancers12051252.
45. Mahfoudh W, Bettaieb I, Ghedira R, Snoussi K, Bouzid N, Klayech Z, et al. [Contribution of BRCA1 5382insC mutation in triplenegativebreast cancer in Tunisia](#). J. Transl Med. 2019;17:123. doi: 10.1186/s12967-019-1873-8

Tables

Table 1:

Clinicopathological parameters and association with *BRCA1*/*BRCA2* carriers

	N (%)	Non carrier (%)	BRCA1 carrier (%)	BRCA2 carrier (%)	P
Family history					
Yes	113 (84.3)	95 (84)	9 (8)	9(8)	0.33
No	21 (15.7)	20 (95.2)	1 (4.8)	0 (0.00)	
Age					
≤30	9 (6.7)	7 (77.8)	1 (11.1)	1(11.1)	0.433
31-40	55 (41)	45 (81.8)	7 (12.7)	3 (5.5)	
41-50	33 (24.6)	29 (87.9)	2 (6.1)	2 (6.1)	
≥51	37 (27.6)	34 (91.4)	0 (0.00)	3 (8.1)	
Tumor site					
Unilateral BC	104 (77.6)	92(91.4)	4 (3.8)	8 (7.7)	0.029
Bilateral BC	6 (4.5)	4 (66.7)	1 (16.7)	1 (16.7)	
OC	22 (16.4)	18 (81.8)	4 (18.2)	0 (0.00)	
OC/BC	2 (1.5)	1(50)	1 (50)	0 (0.00)	
Tumor Grade					
SBR II	82 (73.2)	73 (89)	4 (4.9)	5 (6.1)	0.41
SBR III	30 (26.8)	24 (80)	2 (6.7)	4 (13.3)	
T-stage					
T0-T1	11 (8.2)	9 (81.8)	2 (18.2)	0 (0.00)	0.16
T2	63 (47)	56 (88.9)	2 (3.2)	5(7.9)	
T3	49 (36.6)	41 (83.7)	6 (12.2)	2 (4.1)	
T4	11 (802)	9 (81.1)	0 (0.00)	2 (18.2)	
N-stage					
No	54 (40.3)	48 (88.9)	3 (5.6)	3 (5.6)	0.69
N1-N2	80 (59.7)	67 (83.8)	7 (8.8)	6 (7.5)	
M					
M0	120 (89.6)	105 (87.5)	7 (5.8)	8 (6.7)	0.107
M1	14 (10.4)	10 (71.4)	3 (21.4)	1 (7.1)	
Triple Negative					
No	84 (76.4)	75 (89.3)	1 (1.2)	8 (9.5)	0.008

Yes	26 (23.6)	21 (80.8)	4 (15.4)	1 (3.8)
-----	-----------	-----------	----------	---------

Table 2:

Pathogenic *BRCA1/BRCA2* mutations identified in breast/ovarian cancer patients

Gene	DNA change	Protein change	BIC, ClinVar	Class	Tumor site	Age	Fq
<i>BRCA1</i>	c.4067-4071 delAAGAA	GLn1356Argfs*8	NR	5	Bil BC	30	1
	c.5030_5033delCTAA	Thr1677Ilefs*2	R	6	BC, OC, BC/OC	38,39,40	3
	c.296_297delTG	Leu99*	NR	-	BC	43	1
	c.2338C>T	Gln780*	R	5	OC, OC	46,48	2
	c.3254delG	Arg1085Asnfs*2	NR	5	BC	33	1
	c.3364_3370 dupACAGATT	Phe1124Tyrfs*11	NR	-	BC	40	1
	c.4041_404delAG	Gly1348Asnfs*7	R	4	BC	40	1
	c.17-20 delAAGA	Lys6Argfs*17	NR	5	BC	39	2
	c.1310-1313 delAAGA	Lys437Ilefs*22	R	5	BC	57,42, 27,58	4
<i>BRCA2</i>	c.1796_1800 delCTTAT	Ser599*	R	4	BC	37	1
	c.2095C>T	Gln699*	NR	5	BC	43	1
	c.9097delA	Thr3033Leufs*28	R	5	BC	63	1
	c.632-1G>A	-	R	2	BC	27,57	2

BC: Breast Cancer, OC:Ovarian Cancer, Bil BC: Bilateral Breast Cancer. Fq: frequency of the identified mutation. R: Reported, NR: Not Reported

Table 3:

Association of *BRCA1*/*BRCA2* carriers with tumor site and triple negative status in patients divided according to the age at diagnosis.

Age	Tumor	Site	Non Carriers (%)	BRCA1 carriers (%)	BRCA2 carriers (%)	P
≤ 30	BC		7 (77.8)	1 (11.1)	1 (11.1)	-
	OC		0 (0)	0 (0)	0 (0)	
31-40	BC		44 (86.3)	4 (7.8)	3 (5.9)	0.001
	OC		1 (25)	3 (75)	0 (0)	
41-50	BC		22 (91.7)	0 (0)	2 (8.3)	0.044
	OC		7 (77.8)	2 (22.2)	0 (0)	
≥ 51	BC		23 (88.5)	0 (0)	3 (11.5)	0.24
	OC		11 (100)	0 (0)	0 (0)	
Age	TN		Non Carriers (%)	BRCA1 carriers (%)	BRCA2 carriers (%)	P
≤ 30	No		4 (100)	0 (0)	0 (0)	0.358
	Yes		3 (60)	1 (20)	1 (20)	
31-40	No		34 (89.5)	1 (2.6)	3 (7.9)	0.041
	Yes		10 (76.9)	3 (23.1)	0 (0)	
41-50	No		17 (89.5)	0 (0)	2 (10.5)	0.449
	Yes		5 (100)	0 (0)	0 (0)	
≥ 51	No		20 (87)	0 (0)	3 (13)	0.506
	Yes		3 (100)	0 (0)	0 (0)	

BC: Breast Cancer, OC: Ovarian Cancer (with or without breast cancer)

Yes: TN (ER-/PR-/Her2-), No: Others (ER-/PR-/Her2+, ER+/PR+/Her2+, ER+/PR+/Her2-)

Table 4:
List of the Uncertain Significant Variants of *BRCA1*/*BRCA2*

Variants	Gene	Exon	AA Change	Clinical importance (BIC)	Functional prediction		
					Poly	SIFT	Mutation
					Phen	Taster	
c.293G>C	<i>BRCA1</i>	5	G98A	Unknown	PD	Del	DC
c.397 C>T	//	6	R 133C	//	PD	Del	DC
c.536A>G	//	7	Y179C	//	PD	Del	DC
c.1067A>G	//	11	Q356R	//	PD	D	Pol
c.1648A>C	//	11	N550H	NA	PD	D	Pol
c.5117G>C	//	17	G1706A	//	B	Del	DC
c.6100 C>T	<i>BRCA2</i>	11	R2034C	//	PD	D	Pol
c.7397T>C	//	14	V2466A	No	PD	D	Pol
c.7712A>G	//	16	E2571G	//	PD	D	DC
c.9976A>T	//	27	K3326*	LB	NA	NA	DC

PD: Probably Deleterious; D: Deleterious; DC: Disease Causing; Pol: Polymorphism. LB: Likely Benign; NA: Not Available

Figures




Figure 1

Figure 1

Schematic diagram of BRCA1 and BRCA2 proteins with the position of all identified pathogenic variants. Novel variants are marked with this symbol Δ




Figure 1

Figure 1

Schematic diagram of BRCA1 and BRCA2 proteins with the position of all identified pathogenic variants. Novel variants are marked with this symbol Δ




Figure 2

Figure 2

BRCA mutation rate (%) in all BC (a), in all OC (b), and in TNBC (c) patients divided according to age at diagnosis (\leq 30, 31–40, 41–50, and \geq 51years old).




Figure 2

Figure 2

BRCA mutation rate (%) in all BC (a), in all OC (b), and in TNBC (c) patients divided according to age at diagnosis (\leq 30, 31–40, 41–50, and \geq 51years old).